Back to Research Home
NVSNovartis AG ADR
Health Care · Biotechnology: Pharmaceutical Preparations
$151.12−3.30%
As of 23 Oct 2026Mkt cap —
Stage 13
WAIT
Fundamentals
—/75
Technical
11.5/15
Independent
—/90
GCAE viewevidence is stale or freshness is unknown
Price
- 1M
- +5.3%
- 3M
- −3.2%
- 6M
- +3.9%
- 1Y
- +15.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 23.9%
- Operating margin
- —
- FCF margin
- —
- Current ratio
- 1.1x
Growth
- Revenue growth
- —Latest FY YoY
- Revenue CAGR
- —
- EPS CAGR
- −9.4%
- FCF CAGR
- +5.9%
Capital
- Share-count trend
- −3.3%3Y annualised
- Net debt
- $19.9B1.0x OCF
Annual trend
- CAGR 2021–2025
- −9.4%
- Latest · 2025
- $7.15
- YoY
- +21.8%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
evidence is stale or freshness is unknown
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded